RiMO is addressing unmet medical needs in recurrent and metastatic solid tumors by leveraging its disruptive technology platform. RiMO intends to maximize the potential of this technology platform through in-house development, collaborations, and licensing.
In particular, RiMO technology enhances state-of-the-art immunosuppression inhibitor-based cancer immunotherapy. It significantly increases the efficacy of checkpoint inhibitors and other inhibitors in a number of tumor types in mouse models. RiMO hopes to partner with pharmaceutical companies to significantly increase the response rates of current cancer immunotherapies.
For more information regarding RiMO’s partnering strategy, please contact Dr. Wenbin Lin, Founder and Chairman, at firstname.lastname@example.org.